Delivery Order SPE2DB20D1100-SPE2DB25FD2K8
Award Date
7/3/25
Potential Completion Date
7/25/25
Potential Value
$120K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $48,077.16 firm-fixed-price delivery order contract awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The contract has an ultimate completion date of July 2, 2025 and is not set aside for any particular business category. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $120,192.80 firm fixed-price contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $120,192.80, is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor, and the place of performance...
This is a $115,590.40 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to the Corporate Office Division of Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The order is for 4,564,570,264 units of the drug OCREVUS 300 mg/10 ml vial. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $72,115.74, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of March 31, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product, with a ceiling value of $120,192.80 and a performance period ending on July 9, 2025. The contract is a Firm Fixed Price delivery order, not set aside for any specific business category. AmerisourceBergen Drug Corp...
This is a $24,038.58 firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a medication used to treat multiple sclerosis. The contract has an ultimate completion date of June 5, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite...
This is a delivery order awarded to AmerisourceBergen Drug Corp's Corporate Office Division by the Defense Logistics Agency (DLA). The $231,180.80 firm fixed-price contract is for the supply of 4,565,214,858 units of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product. The contract has an ultimate completion date of August 9, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $180,289.20, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a medication used to treat multiple sclerosis. The contract has a performance period through June 4, 2025 and is not set aside for any specific business category. AmerisourceBergen Drug Corp holds a larger...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $72,115.74, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription medication. The contract is a firm fixed price, non-set-aside award with a completion date of June 25, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA...